This study demonstrates that, among patients with breast or ovarian cancer, positive genetic test results in ATM, CHEK2, PALB2, and other DDR genes impact clinical recommendations for the majority of patients and/or their family members. This evidence concerns the gene DDR1 and ovarian cancer.